Automating Complex Assembly: What the Transition Actually Looks Like

There is a recurring gap between how automation appears on a project plan and how it actually survives on the factory floor. For a COO or Head of Operations, the transition from clinical assembly to a fully automated commercial line is often framed as a production ramp. In reality, it is a discrete engineering project. The small-scale clinical line, defined by manual fixtures and the institutional knowledge of a few experienced technicians, does not become a high-speed automated line simply by adding robotics. To scale, the design itself must change.

Moving a multi-component mechanical device into high-volume production requires a fundamental shift: you are no longer engineering the device for the patient; you are re-engineering the device for the process.

Why Automation Does Not Follow Directly From Clinical Assembly

At clinical volumes, manual assembly is frequently the optimal choice. Small lots allow experienced assemblers to use their judgment to absorb component variability, and 100% manual inspection can catch defects that a rigid machine might miss. However, this creates a dangerous trap: the assembly line is designed around the people on it, not the process itself.

When those people cannot be scaled, the line cannot scale. Automation requires that the assembly process produces an identical result every single time without relying on operator judgment for a single quality-affecting step. This means device design, component tolerances, and assembly sequences must be evaluated for “automation readiness” long before equipment is selected.

It is a common mistake to assume that Design for Manufacturability (DFM) for a molded part is the same as DFM for automation. A component can be easy to injection mold and yet remain nearly impossible to orient or feed on an automated line. Manual assembly creates a level of variability that high-speed automation simply cannot absorb.

The DFM-for-Automation Review: What Actually Changes

A DfM review specifically for automation addresses questions that clinical-stage engineering often overlooks. When we evaluate a complex mechanical assembly for high-speed production, we focus on four critical gates:

• Orientation and Feeding: If a part relies on an operator’s tactile judgment to orient—due to asymmetric geometries or thin walls—it requires a design modification. If the geometry isn’t “robot-friendly,” the component must be redesigned before hard tooling is cut.
• Tolerance Stack-Up: Manual assembly absorbs variation through human adjustment. Automated systems do not. A rigorous tolerance stack-up analysis is the first mandatory engineering gate for automation viability.
• Force-Feedback Replacement: Any step where an assembler “feels” for correct engagement—such as a needle seating or a snap-fit—must be replaced with self-locating features or expensive force-sensing systems.
• Inline Verification: Quality must be verified without stopping the line. Vision inspection systems must be integrated into the architecture from the start. This includes defining camera angles, lighting conditions, and part orientation for inspection during the initial line design.

To mitigate these risks, utilizing virtual molding simulation tools like SIGMASOFT is a must. This allows for evaluating material flow and weld line formation across the full component to ensure molded parts behave consistently at volume before committing to steel.

The Four Phases of a Disciplined Transition

Successful transitions follow a structured sequence. Rushing any phase typically results in “automation stall” during the ramp.

1. Automation Readiness Assessment: We evaluate the current device design against high-speed requirements, identifying exactly what must change in the geometry before the line design begins.
2. Design-for-Automation Iteration: Components are modified or consolidated. Part reduction is the primary objective; fewer parts mean fewer feeding systems and fewer opportunities for assembly error. The design must be frozen here, before hard tooling is cut.
3. Line Design and Validation: The automated line is built around the revised geometry. This includes the IQ/OQ/PQ validation sequence required for regulated medical devices.
4. Controlled Production Ramp: First runs are a data collection phase. We establish Statistical Process Control (SPC) baselines for key quality parameters. A unified data architecture allows for “compliance by default,” where Device History Records (DHRs) and full traceability are generated automatically.

Where the Transition Typically Stalls

In our experience, the most common failures are predictable. Many programs treat automation as a production ramp rather than a design problem. They proceed to line design without a DFM-for-automation review, only to discover that a feeding system cannot handle a component consistently. Fixing this requires modifying component design after the tooling commitment—an expensive and time-consuming error.

Furthermore, when vision inspection is added as an afterthought rather than designed into the architecture, it is often imprecise. This forces the manufacturer into 100% end-of-line manual inspection at high volumes, which is neither cost-effective nor viable for maintaining a 0.10% defect rate.

What “Good” Looks Like in Practice

To illustrate the impact of this approach, consider a program our team managed for a precision mechanical device component. This program moved from approximately 10,000 units per year in semi-manual production to over one million units per year in a fully automated configuration.

The transition was not a simple speed-up. It involved two rounds of component redesign before tooling was cut and a six-month controlled ramp to establish process stability. By engineering repeatability into the design from the start, the final cost-per-unit was reduced by approximately 70%, materially changing the economics of the entire program.

Conclusion

The device that successfully passes clinical trials is often not the device that will run efficiently on a commercial, high-speed automated line. As you look at your own production roadmap, ask one question: Was this design ever evaluated specifically for the feeding, orientation, and inspection requirements of a robot?

If the answer is no, that evaluation is your starting point. The earlier the gap between clinical assembly and commercial automation is identified, the more options you have to protect your margins and your timeline.

About the Author 

Josh Scott, Sr. Director of Automation and R&D, brings 28+ years of industry experience and a passion for turning complex product concepts into high-speed, high-precision reality. Since joining Tessy in 2020, he’s led the charge in automated assembly and technical innovation guided by the belief that “quality is a mindset”, delivering cutting-edge systems for medical devices, diagnostic kits, and consumer goods.